| Ytd | -17.38% | |
| 1y | 113.57% |
| Open | 35.39 | Prev Close | 34.29 | Low | 32.79 | High | 36.52 | Mkt Cap | 86.47M |
| Vol | 0.00 | Avg Vol | 71.53K | EPS | -1.06 | P/E | -31.17 | Forward P/E | -42.03 |
| Beta | 0.63 | Short Ratio | 1.50 | Inst. Own | 14.95% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-14 | 50-d Avg | 33.35 | 200-d Avg | 33.65 | 1yr Est | 35.00 |
VTVT News
Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes (T1D) expected to
HIGH POINT, N.C., July 28, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-sta
Recent analyst rating changes, top names such as PPG, SAH, ISRG, MMM, OKE, GLDG, ABT, NFLX, TSCO, an
Top Wall Street analysts changed their outlook on top names. See all changes, including upgrades and
BTIG analyst Kambiz Yazdi maintains vTv Therapeutics (NASDAQ:VTVT) with a Buy and raises the pric
HIGH POINT, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-sta
HIGH POINT, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-sta
If you are looking for stocks that are well positioned to maintain their recent uptrend, vTv Therape
Phase 3 CATT1 completion of enrollment on track for the third quarter of 2026 Strong balance sheet e
HIGH POINT, N.C., May 08, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stag
HIGH POINT, N.C., May 07, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stag
The mean of analysts' price targets for vTv Therapeutics (VTVT) points to a 39.9% upside in the stoc
HIGH POINT, N.C., April 07, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-st
The mean of analysts' price targets for vTv Therapeutics (VTVT) points to a 31.6% upside in the stoc
The average of price targets set by Wall Street analysts indicates a potential upside of 39.9% in vT
HIGH POINT, N.C., March 16, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-st
Wall Street analysts change outlook on top companies. See analyst rating changes and their thoughts
Top Wall Street analysts changed their outlook on top names, including WLTH, FPI, CAG, VIV, and GIS.
Received $20.0 million in February 2026 from Newsoara under an amended licensing agreement Expect to
I think VTVT is a largely underfollowed T1D catalyst story, with Phase 3 CATT1 cadisegliatin topline
vTv Therapeutics Inc. (NASDAQ: VTVT - Get Free Report) saw a large growth in short interest during t
HIGH POINT, N.C., Feb. 13, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-sta
Strategic amendment transforms regional partnership into global collaboration; Newsoara gains exclus
vTv Therapeutics (VTVT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism abou
Trial to assess cadisegliatin as potential adjunctive therapy to insulin in patients with T2D Trial
Gainers Harbor Custom Development, Inc. (NASDAQ: HCDI) rose 74.2% to $1.50 after surging 24% on Th
On Wednesday, 807 companies reached new 52-week lows.
Tuesday's session saw 729 companies set new 52-week lows.
During Tuesday's morning trading, 87 companies set new 52-week lows.
Gainers ZIVO Bioscience, Inc. (NASDAQ: ZIVO) shares jumped 76.2% to $6.08.
Gainers Focus Universal Inc. (NASDAQ: FCUV) rose 42% to $15.24 in pre-market trading. The company
Gainers
Stocks That Hit 52-Week Highs On Monday
45 Biggest Movers From Yesterday
28 Stocks Moving In Monday's Pre-Market Session